Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms × Hydralazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 3 Refractory Solid Tumors 1 Rectal Neoplasms 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Breast Neoplasms 1

Interventions

Trastuzumab 527 Paclitaxel 501 Cyclophosphamide 482 Docetaxel 425 Capecitabine 359 Letrozole 312 Fulvestrant 276 Doxorubicin 254 Carboplatin 241 Tamoxifen 227 Anastrozole 189 exemestane 182 Radiotherapy 181 Epirubicin 179 Bevacizumab 172 Vinorelbine 151 Lapatinib 151 Gemcitabine 149 pembrolizumab 145 pertuzumab 143 palbociclib 135 Exercise 116 Albumin-Bound Paclitaxel 107 Magnetic Resonance Spectroscopy 104 Fluorouracil 104 eribulin 99 130-nm albumin-bound paclitaxel 95 Everolimus 90 Taxes 85 Cisplatin 84

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00575978 2015-03-04

Hydralazine as Demethylating Agent in Breast Cancer

University of Arkansas

Phase 1/2 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡